Analysts’ Top Healthcare Picks: Acceleron Pharma (XLRN), Incyte Corp (INCY)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Acceleron Pharma (XLRNResearch Report) and Incyte Corp (INCYResearch Report) with bullish sentiments.

Acceleron Pharma (XLRN)

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Acceleron Pharma yesterday and set a price target of $78.00. The company’s shares closed last Monday at $39.47, close to its 52-week low of $37.01.

According to, Werber is a 4-star analyst with an average return of 5.1% and a 50.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Springworks Therapeutics Inc, and Rocket Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acceleron Pharma with a $59.10 average price target.

See today’s analyst top recommended stocks >>

Incyte Corp (INCY)

Cowen & Co. analyst Marc Frahm reiterated a Buy rating on Incyte Corp yesterday. The company’s shares closed last Monday at $76.12.

According to, Frahm ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -6.6% and a 38.9% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Magenta Therapeutics Inc, and Applied Therapeutics Inc.

Incyte Corp has an analyst consensus of Moderate Buy, with a price target consensus of $94.83, a 24.3% upside from current levels. In a report issued on October 2, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $95.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.